| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6124304 | MYLAN | Penciclovir for the treatment of zoster associated pain |
Oct, 2014
(9 years ago) | |
| US5866581 | MYLAN | Penciclovir for the treatment of post therapeutic neuralgia |
Oct, 2014
(9 years ago) | |
| US5840763 | MYLAN | Treatment of a latent infection of herpes viruses |
Sep, 2015
(8 years ago) | |
| US5916893 | MYLAN | Treatment of a latent infection of herpes virus |
Sep, 2015
(8 years ago) | |
| US6469015 | MYLAN | Pharmaceutical formulation |
Oct, 2019
(4 years ago) | |
| US6579981 | MYLAN | Antiviral guanine derivatives |
Jun, 2020
(3 years ago) | |
Denavir is owned by Mylan.
Denavir contains Penciclovir.
Denavir has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Denavir are:
- US6124304
- US5866581
- US5840763
- US5916893
- US6469015
- US6579981
Denavir was authorised for market use on 24 September, 1996.
Denavir is available in cream;topical dosage forms.
Denavir can be used as treatment of recurrent herpes labialis (cold sores) in adults.
The generics of Denavir are possible to be released after 17 June, 2020.
Drugs and Companies using PENCICLOVIR ingredient
Market Authorisation Date: 24 September, 1996
Treatment: Treatment of recurrent herpes labialis (cold sores) in adults
Dosage: CREAM;TOPICAL
More Information on Dosage
DENAVIR family patents
